| Original language | English |
|---|---|
| Pages (from-to) | E008971 |
| Journal | Circulation: Heart Failure |
| Volume | 15 |
| Issue number | 4 |
| DOIs | |
| State | Published - Apr 1 2022 |
Keywords
- angiotensins
- costs and cost analysis
- global health
- heart failure
- mineralocorticoids
Access to Document
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
Access to Heart Failure Medicines in Low- and Middle-Income Countries : An Analysis of Essential Medicines Lists, Availability, Price, and Affordability. / Agarwal, Anubha; Husain, Muhammad Jami; Datta, Biplab et al.
In: Circulation: Heart Failure, Vol. 15, No. 4, 01.04.2022, p. E008971.Research output: Contribution to journal › Article › peer-review
TY - JOUR
T1 - Access to Heart Failure Medicines in Low- and Middle-Income Countries
T2 - An Analysis of Essential Medicines Lists, Availability, Price, and Affordability
AU - Agarwal, Anubha
AU - Husain, Muhammad Jami
AU - Datta, Biplab
AU - Kishore, Sandeep P.
AU - Huffman, Mark D.
N1 - Funding Information: Dr Agarwal was supported by a postgraduate fellowship in global health by the Institute of Global Health at Northwestern University for this research. Funding Information: In the past 3 years, Dr Huffman received funding from the World Heart Federation to serve as its senior program advisor for the Emerging Leaders program, which has been supported by Boehringer Ingelheim, Novartis, Bupa, and AstraZeneca. Dr Huffman also received support from the American Heart Association, Verily, and AstraZeneca and American Medical Association for work unrelated to this research. The George Institute for Global Health’s wholly owned enterprise, George Health Enterprises, has received investment funds to develop fixed-dose combination products containing aspirin, statin, and blood pressure–lowering drugs. Drs Huffman and Agarwal plan to submit patents for heart failure polypills. Dr Kishore has served as a consultant for Resolve to Save Lives for hypertension control and has previously led a partnership on multiple chronic conditions with the Icahn School of Medicine at Mount Sinai and Teva Pharmaceuticals. The findings and conclusions of this report are those of authors only and do not necessarily represent the official position of the Centers for Disease Control and Prevention. The other authors report no conflicts.
PY - 2022/4/1
Y1 - 2022/4/1
KW - angiotensins
KW - costs and cost analysis
KW - global health
KW - heart failure
KW - mineralocorticoids
UR - http://www.scopus.com/inward/record.url?scp=85128800075&partnerID=8YFLogxK
U2 - 10.1161/CIRCHEARTFAILURE.121.008971
DO - 10.1161/CIRCHEARTFAILURE.121.008971
M3 - Article
C2 - 35249355
AN - SCOPUS:85128800075
SN - 1941-3289
VL - 15
SP - E008971
JO - Circulation: Heart Failure
JF - Circulation: Heart Failure
IS - 4
ER -